Brexit

View All

Notizia

FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi.  As Tegsedi is approved,...

Find More

Innovate the UK, aiming to drive efforts to commercialize research

The government of UK announced an extra £4.7 billion (US$6.1 billion) into research and development (R&D) by 2020–21, which allayed the fears of many UK scientists which had erupted ahead of Brexit. In this announcement, the biggest winner will be an innovation agency, Innovate UK. Previously known as Technology...

Find More

AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer

AstraZeneca's new benralizumab helps severe asthma patients cut back on steroids AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on—or even stop—the unsavory steroid pills they use daily to stave off attacks, a new study showed. Dubbed Zonda, the phase 3 trial found tha...

Find More

Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A

Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...

Find More

Whitepaper: Impact of Brexit on Pharma Space

BREXIT shook the whole world when United Kingdom voted in favour of leaving the EU. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenario. Brexit has led to deliberations regarding modified supply chain requirements, uncertain regulatory scenario, revised ...

Find More

The Snippet: Delay in hiring science advisers intensifies Brexit worries

Two government departments charged with managing the United Kingdom’s departure from the European Union have not yet appointed chief scientific advisers (CSAs) — and might not do so. That is starting to concern science-policy experts, who worry that scientists won’t be at the table when government makes key decision...

Find More